HomeAI · summaries
Storia in 2 fonti
Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
- ·
endpoints.news
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
Latigo Biotherapeutics' non-opioid LTG-001 reduced acute pain in Phase 2b, competing with Vertex's Journavx; Phase 3 trial planned for late 2026.